Press Releases

Biophytis announces the design of its phase 2 OBA clinical study in obesity Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, together with hypocaloric dieting. The OBA phase 2 study will test the efficacy and safety of BIO101 (20-hydroxyecdysone) in patients with obesity and overweight with secondary comorbidities, who are starting treatment with GLP-1 RAs for weight loss. Stanislas Veillet, CEO of Biophytis, stated: “It is crucial for Biophytis to position itself on this gigantic medical challenge which also presents

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Biophytis annouces that it will change the ratio of its American Depositary Shares (the “ADSs”) to Biophytis ordinary shares (the “Shares”) from one ADS representing 100 Shares, to one ADS representing 4,000 Shares (the “Ratio Change”). The effective date of the Ratio Change (the “Effective Date”) is expected to be April 23, 2024. Pursuant to the Ratio Change, as of the Effective Date, record holders who directly hold ADRs will be required to exchange their existing ADRs for new ADRs on the basis of one new ADR for every

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming weeks Biophytis announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity. This Scientific Advisory Board will be composed of a few worldwide medical experts in the field of obesity, including Professor Dennis Villareal from the USA and Professor Francisco Guarner from Spain. The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively

Biophytis files a patent application and strengthens its intellectual property in obesity Biophytis announces the filing of a patent application in the treatment of obesity, a new indication in which the Company has positioned itself with the announcement of its phase 2 OBA clinical trial. This new patent application, which is expected to be granted as soon as 2025, will strengthen BIO101’s (20-hydroxyecdysone) position in the treatment of obesity in combination with GLP-1 RAs. This new patent will extend the exclusivity period of BIO101 (20-hydroxyecdysone) in this indication until 2044. Stanislas Veillet, CEO de Biophytis comments: “This patent application completes

Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis publishes its financial results for the year ended December 31, 2023, and provides an update on the progress of its various programmes. “In 2023, despite a particularly difficult financial environment for the biotech sector, we succeeded in pursuing the development of our clinical programmes, while securing the company’s financing until early 2025,” states Stanislas Veillet, CEO of Biophytis. “We were able to confirm the therapeutic value of BIO101 (20-hydroxyecdysone), our lead drug candidate, in the treatment of patients suffering from severe forms of COVID-19, opening

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 30% of the shareholders present or represented. The resolutions, which notably included a renewal of the usual financial delegations granted to the Company, were all approved. The results of the votes are available in the Investors / General Meetings section. Fullscreen Mode

Biophytis presented its phase 3 protocol in the treatment of sarcopenia Biophytis presented its phase 3 protocol aimed at demonstrating the potential of Ruvembri™ (20-hydroxyecdysone) in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research (ICFSR), held from March 20 to 22, 2024 in Albuquerque, NM, USA. The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population. This outcome was replicated in pre-defined sub-populations at higher risk of mobility